Gene fusions involving MYB, MYBL1, and NFIB, which were found in nearly 90% of our SAdCC cases, are currently considered to be the primary oncogenetic event in SAdCC [8, 9], and RAS mutations may confer progressive or invasive features on the tumor cells, resulting in a worse prognosis for SAdCC patients. This evidence concerns the gene NFIB and neoplasm.